锦欣生殖（HK01951，股价2.32港元，市值63.68亿港元）发布的2025年财报显示，公司全年营业收入26.49亿元（人民币，下同），经调整EBITDA（息税折旧及摊销前利润）达4.91亿元，取卵周期数为28039个。尽管上半年受海外商誉资产减值拖累，但下半年业绩全面回暖，经调整净利润环比大增54.9%。 对此，多家机构分析认为，2025年上半年业绩下降主要是海外商誉资产减值所致，下半年...
Source Link锦欣生殖（HK01951，股价2.32港元，市值63.68亿港元）发布的2025年财报显示，公司全年营业收入26.49亿元（人民币，下同），经调整EBITDA（息税折旧及摊销前利润）达4.91亿元，取卵周期数为28039个。尽管上半年受海外商誉资产减值拖累，但下半年业绩全面回暖，经调整净利润环比大增54.9%。 对此，多家机构分析认为，2025年上半年业绩下降主要是海外商誉资产减值所致，下半年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.